Glaxosmithkline Pharmaceuticals Ltd vs Infinium Pharmachem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2361 as of 04 May 10:01 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Infinium Pharmachem Ltd changed from 28.2 on March 2024 to 46.3 on March 2025 . This represents a CAGR of 28.13% over 2 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Infinium Pharmachem Ltd changed from ₹ 318.68 crore on March 2024 to ₹ 376.96 crore on March 2025 . This represents a CAGR of 8.76% over 2 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Infinium Pharmachem Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Infinium Pharmachem Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Infinium Pharmachem Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Infinium Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Infinium Pharmachem Ltd

Infinium Pharmachem Limited was originally incorporated as 'Infinium Pharmachem Private Limited' on November 21, 2003 issued by the Registrar of Companies, Gujarat.
Later on, Company converted its status into Public Company and the name of Company was changed to 'Infinium Pharmachem Limited' vide fresh Certificate of Incorporation dated August 12, 2022.
Company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.
The Company has its manufacturing plant at Dist.
Anand, Gujarat, since inception. The Company's manufacturing capabilities and technical expertise have catered industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics, etc.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Infinium Pharmachem Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Infinium Pharmachem Ltd is 336 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Infinium Pharmachem Ltd stock price is INR ₹216.25.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Infinium Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.